iNFixion Bioscience has been awarded a NIH (NINDS) Phase 1 SBIR grant to pursue proof-of-principal research into studying the mechanisms and identifying drug compounds that impact transcriptional regulation of the NF1 gene. The grant aims include the development of a new NF1 reporter cell line, high throughput screening of multiple compound libraries, and the in vitro validation of compound hits on NF1 protein pathway effectors. With the announcement of this Phase 1 grant award, iNFixion Bioscience has hired its first full-time PhD scientist researcher (Dr. Michelle Mattson-Hoss, PhD) and has been accepted as a resident company at the prestigious San Diego JLABS innovation accelerator. Hands-on laboratory experimentation is now underway.
To learn more about JLABS click here!